S&P 500   3,333.38 (+0.38%)
DOW   29,291.20 (+0.33%)
QQQ   224.56 (+0.57%)
AAPL   318.13 (+0.49%)
MSFT   167.15 (+0.39%)
GOOGL   1,492.33 (+0.68%)
AMZN   1,890.00 (-0.11%)
CGC   24.58 (+1.78%)
NVDA   250.46 (+1.02%)
BABA   225.08 (+1.27%)
MU   59.95 (+1.66%)
GE   11.68 (+0.17%)
TSLA   568.91 (+3.97%)
AMD   51.60 (+1.08%)
ACB   2.00 (-0.50%)
F   9.22 (+0.11%)
NFLX   330.12 (-2.36%)
PRI   126.41 (+0.00%)
BAC   34.41 (+0.44%)
DIS   143.79 (+0.16%)
GILD   62.75 (+0.19%)
S&P 500   3,333.38 (+0.38%)
DOW   29,291.20 (+0.33%)
QQQ   224.56 (+0.57%)
AAPL   318.13 (+0.49%)
MSFT   167.15 (+0.39%)
GOOGL   1,492.33 (+0.68%)
AMZN   1,890.00 (-0.11%)
CGC   24.58 (+1.78%)
NVDA   250.46 (+1.02%)
BABA   225.08 (+1.27%)
MU   59.95 (+1.66%)
GE   11.68 (+0.17%)
TSLA   568.91 (+3.97%)
AMD   51.60 (+1.08%)
ACB   2.00 (-0.50%)
F   9.22 (+0.11%)
NFLX   330.12 (-2.36%)
PRI   126.41 (+0.00%)
BAC   34.41 (+0.44%)
DIS   143.79 (+0.16%)
GILD   62.75 (+0.19%)
S&P 500   3,333.38 (+0.38%)
DOW   29,291.20 (+0.33%)
QQQ   224.56 (+0.57%)
AAPL   318.13 (+0.49%)
MSFT   167.15 (+0.39%)
GOOGL   1,492.33 (+0.68%)
AMZN   1,890.00 (-0.11%)
CGC   24.58 (+1.78%)
NVDA   250.46 (+1.02%)
BABA   225.08 (+1.27%)
MU   59.95 (+1.66%)
GE   11.68 (+0.17%)
TSLA   568.91 (+3.97%)
AMD   51.60 (+1.08%)
ACB   2.00 (-0.50%)
F   9.22 (+0.11%)
NFLX   330.12 (-2.36%)
PRI   126.41 (+0.00%)
BAC   34.41 (+0.44%)
DIS   143.79 (+0.16%)
GILD   62.75 (+0.19%)
S&P 500   3,333.38 (+0.38%)
DOW   29,291.20 (+0.33%)
QQQ   224.56 (+0.57%)
AAPL   318.13 (+0.49%)
MSFT   167.15 (+0.39%)
GOOGL   1,492.33 (+0.68%)
AMZN   1,890.00 (-0.11%)
CGC   24.58 (+1.78%)
NVDA   250.46 (+1.02%)
BABA   225.08 (+1.27%)
MU   59.95 (+1.66%)
GE   11.68 (+0.17%)
TSLA   568.91 (+3.97%)
AMD   51.60 (+1.08%)
ACB   2.00 (-0.50%)
F   9.22 (+0.11%)
NFLX   330.12 (-2.36%)
PRI   126.41 (+0.00%)
BAC   34.41 (+0.44%)
DIS   143.79 (+0.16%)
GILD   62.75 (+0.19%)
Log in

NASDAQ:ZLAB - Zai Lab Stock Price, Forecast & News

$50.35
-1.79 (-3.43 %)
(As of 01/22/2020 09:39 AM ET)
Today's Range
$49.08
Now: $50.35
$51.75
50-Day Range
$38.39
MA: $42.49
$53.10
52-Week Range
$23.42
Now: $50.35
$53.48
Volume25,942 shs
Average Volume230,305 shs
Market Capitalization$2.93 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.4
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZLAB
CUSIPN/A
Phone86-21-6163-2588

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$130,000.00
Price / Sales22,502.58
Book Value$4.32 per share

Profitability

Miscellaneous

Employees309
Market Cap$2.93 billion
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.


Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

When is Zai Lab's next earnings date?

Zai Lab is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Zai Lab.

What price target have analysts set for ZLAB?

6 equities research analysts have issued 12 month price objectives for Zai Lab's stock. Their forecasts range from $34.70 to $84.00. On average, they anticipate Zai Lab's share price to reach $49.25 in the next twelve months. This suggests that the stock has a possible downside of 5.5%. View Analyst Price Targets for Zai Lab.

What is the consensus analysts' recommendation for Zai Lab?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zai Lab.

Has Zai Lab been receiving favorable news coverage?

Headlines about ZLAB stock have been trending negative recently, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zai Lab earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Zai Lab.

Are investors shorting Zai Lab?

Zai Lab saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,510,000 shares, an increase of 10.2% from the December 15th total of 1,370,000 shares. Based on an average trading volume of 178,600 shares, the days-to-cover ratio is presently 8.5 days. Currently, 2.5% of the shares of the company are sold short. View Zai Lab's Current Options Chain.

Who are some of Zai Lab's key competitors?

What other stocks do shareholders of Zai Lab own?

Who are Zai Lab's key executives?

Zai Lab's management team includes the folowing people:
  • Dr. Ying Du, Founder, Chairman & CEO (Age 53)
  • Mr. Tao Fu, Pres, COO & Director (Age 47)
  • Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
  • Dr. Ning Xu, Exec. VP and Head of Clinical & Regulatory Affairs (Age 54)
  • Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54)

When did Zai Lab IPO?

(ZLAB) raised $100 million in an IPO on Wednesday, September 20th 2017. The company issued 5,900,000 shares at $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners served as the underwriters for the IPO.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $52.14.

How big of a company is Zai Lab?

Zai Lab has a market capitalization of $3.03 billion and generates $130,000.00 in revenue each year. The company earns $-139,070,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. Zai Lab employs 309 workers across the globe.View Additional Information About Zai Lab.

What is Zai Lab's official website?

The official website for Zai Lab is http://www.zailaboratory.com/.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]


MarketBeat Community Rating for Zai Lab (NASDAQ ZLAB)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  204 (Vote Underperform)
Total Votes:  376
MarketBeat's community ratings are surveys of what our community members think about Zai Lab and other stocks. Vote "Outperform" if you believe ZLAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZLAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel